<DOC>
	<DOC>NCT02547714</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of secukinumab at Week 16 based on psoriasis area and severity index (PASI) 75 in subjects who had inadequate response to cyclosporine A.</brief_summary>
	<brief_title>Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Inclusion criteria: Plaque psoriasis diagnosed for at least 6 months before baseline Treated with cyclosporine A for at least 12 weeks prior to baseline Currently treated with cyclosporine A at baseline for psoriasis but is a primary or secondary inadequate response as defined at baseline by: PASI score of 10 or greater and IGA mod 2011 score of 2 or greater (based on a scale of 0 to 4) Forms of psoriasis other than plaque (e.g., pustular, erythrodermic and guttate psoriasis). Druginduced psoriasis (i.e., new onset or current exacerbation from betablockers, calcium channel blockers or lithium). Patients who have to discontinue cyclosporine A treatment due to side effects like renal impairment (serum creatinine exceeding 176.8 Î¼mol/L [2.0 mg/dL]) and hypertension at screening. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cyclosporine A</keyword>
</DOC>